Immunovant, Inc. (IMVT)

Immunovant Statistics

Total Valuation

Immunovant has a market cap or net worth of $5.28 billion. The enterprise value is $4.29 billion.

Market Cap	5.28B
Enterprise Value	4.29B

Important Dates

The last earnings date was Friday, February 6, 2026, before market open.

Earnings Date	Feb 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Immunovant has 203.53 million shares outstanding. The number of shares has increased by 18.37% in one year.

Current Share Class	203.53M
Shares Outstanding	203.53M
Shares Change (YoY)	+18.37%
Shares Change (QoQ)	+4.53%
Owned by Insiders (%)	0.59%
Owned by Institutions (%)	47.30%
Float	89.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	5.35
P/TBV Ratio	5.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.74

Current Ratio	15.74
Quick Ratio	15.03
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -69.35% and return on invested capital (ROIC) is -45.49%.

Return on Equity (ROE)	-69.35%
Return on Assets (ROA)	-41.33%
Return on Invested Capital (ROIC)	-45.49%
Return on Capital Employed (ROCE)	-49.40%
Weighted Average Cost of Capital (WACC)	7.69%
Revenue Per Employee	n/a
Profits Per Employee	-$1.28M
Employee Count	362
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Immunovant has paid $3.64 million in taxes.

Income Tax	3.64M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +32.89% in the last 52 weeks. The beta is 0.63, so Immunovant's price volatility has been lower than the market average.

Beta (5Y)	0.63
52-Week Price Change	+32.89%
50-Day Moving Average	25.64
200-Day Moving Average	19.32
Relative Strength Index (RSI)	49.61
Average Volume (20 Days)	1,543,807

Short Selling Information

The latest short interest is 16.93 million, so 8.32% of the outstanding shares have been sold short.

Short Interest	16.93M
Short Previous Month	16.14M
Short % of Shares Out	8.32%
Short % of Float	19.02%
Short Ratio (days to cover)	9.42

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-487.17M
Pretax Income	-460.56M
Net Income	-464.20M
EBITDA	-486.75M
EBIT	-487.17M
Earnings Per Share (EPS)	-$2.68

Balance Sheet

The company has $994.53 million in cash and n/a in debt, with a net cash position of $994.53 million or $4.89 per share.

Cash & Cash Equivalents	994.53M
Total Debt	n/a
Net Cash	994.53M
Net Cash Per Share	$4.89
Equity (Book Value)	986.14M
Book Value Per Share	4.85
Working Capital	976.68M

Cash Flow

In the last 12 months, operating cash flow was -$422.89 million and capital expenditures -$201,000, giving a free cash flow of -$423.09 million.

Operating Cash Flow	-422.89M
Capital Expenditures	-201,000
Free Cash Flow	-423.09M
FCF Per Share	-$2.08

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunovant does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.37%
Shareholder Yield	-18.37%
Earnings Yield	-8.79%
FCF Yield	-8.01%

Analyst Forecast

The average price target for Immunovant is $30.78, which is 18.66% higher than the current price. The consensus rating is "Buy".

Price Target	$30.78
Price Target Difference	18.66%
Analyst Consensus	Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2